AUSTIN, Texas, Aug. 18, 2014 /PRNewswire-iReach/ -- Nitric oxide supplementation using a Neo40® lozenge significantly helps promote normal blood pressure, as indicated by a 30-day, blinded, placebo-controlled clinical study, conducted at the California Medical Institute by renowned cardiology researcher Dr. Ernst Schwarz. Prehypertension is a condition of having elevated blood pressure, but not to the level considered to be high blood pressure.
The clinical study, published in the summer of 2014, included 30 adult patients between the ages of 18 and 80. As part of the study, patients were each advised to ingest one Neo40 nitric oxide supplement lozenge twice a day for 30 days.
Neo40 helps increase nitric oxide levels in the body. The discovery of nitric oxide was awarded a Nobel Prize in 1998 in Physiology or Medicine. Nitric oxide is said to be one of the most important discoveries in cardiovascular medicine because the molecule helps the body dilate blood vessels, increase circulation, and regulate the cardiovascular system.
Developed by Neogenis® Labs, whose team members include scientists and doctors at the University of Texas System, Neo40® is a daily supplement lozenge that helps replenish the body’s nitric oxide levels. Neo40 is scientifically formulated to help relax the arterial walls, supporting circulatory health and blood pressure.
At the trial’s conclusion, doctors noted that Neo40 helps promote normal blood pressure and led to a 12 point reduction in systolic blood pressure and 6 point drop in diastolic blood pressure after 30 days. In addition, patients’ metabolic health was improved. When tested on physical endurance and functional capacity, patients could walk for longer periods of time and could walk further distances.
“Promoting normal blood pressure levels is an important part of maintaining overall cardiovascular health,” says Dr. Ernst Schwarz. “We were certainly impressed by the results of the Neo40 nitric oxide supplementation on blood pressure response and overall wellbeing. These findings represent a promising, nutritionally-oriented option for promoting normal blood pressure in individuals whose blood pressure is at the higher end of normal.”
Dr. Ernst Schwarz, MD, PhD, is attending cardiologist and Professor of Medicine at Cedars-Sinai Medical Center. As a clinician and scientist, he has lectured all over the world and has written more than 150 articles for peer-reviewed publications.
Assistant Professor of Molecular Medicine Dr. Nathan Bryan at the University of Texas at Houston commented, “We, in the medical research community, are excited about Neo40’s potential to help support healthy blood pressure.”
Neogenis® Labs is the leader in nitric oxide research. It’s a company of scientists and researchers who are pushing forward to uncover the best nitric oxide science. The goal is to promote overall health and wellbeing by utilizing the best nature and science have to offer.
Find an online link to the published clinical study here. http://cpt.sagepub.com/content/early/2014/06/17/1074248414539563
Media Contact: Catenya McHenry, Orca Communications Unlimited, LLC, 310-916-9819, catenya@orcapr.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Neogenis® Labs
Help employers find you! Check out all the jobs and post your resume.
